Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look into strategic alternatives for the company.

The Innsbruck-based biotechnology company Cyprumed GmbH is making international headlines with a multi-million dollar license deal: Together with the ...

DBS Bank dominates LinkedIn’s 2025 Top Companies in Singapore list for the third time in a row, topping the best companies ...